NCT04090567 2026-03-05
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
11 trialsNCT04487587 2025-02-26
COMICE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Active not recruiting
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03117933 2024-01-23
OCTOVA
University of Oxford
Phase 2 Completed
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT04184518 2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2 Withdrawn
NCT01337401 2019-01-24
CASPS
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT01310855 2017-05-31
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
University College, London
Phase 2 Terminated
NCT00588900 2017-04-05
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00326599 2017-03-21
Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01262612 2013-07-15
Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion
Radboud University Medical Center
Phase 2 Terminated